Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1Phase 2 1Phase 1/2 1

Status

Active not recruiting 3Withdrawn 1Completed 1

Sponsor Class

INDUSTRY 5

Study Type

Interventional 5Expanded_access 1

Sponsor

Cancer Type

Thoracic 5

Conditions

Carcinoma, Non-Small-Cell Lung 5Lung Neoplasms 1

Interventions

pembrolizumab 1019Carboplatin 959Paclitaxel 932Gemcitabine 793Cisplatin 748Docetaxel 682Bevacizumab 610Pemetrexed 502Nivolumab 486Cyclophosphamide 466Capecitabine 461Fluorouracil 417Dexamethasone 402Rituximab 372Oxaliplatin 347Injections 342atezolizumab 297Trastuzumab 297Leucovorin 286Cetuximab 282Irinotecan 266130-nm albumin-bound paclitaxel 252Prednisone 244Doxorubicin 240Ipilimumab 226Lenalidomide 220Fulvestrant 217fludarabine 214durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × mobocertinib × Clear all
NCT03807778 2026-05-14

A Study of Mobocertinib in Japanese Adults With Non-Small Cell Lung Cancer

Takeda

Phase 1 Active not recruiting
53 enrolled 38 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04129502 2026-03-30

TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

Takeda

Phase 3 Active not recruiting
354 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02716116 2026-02-25

A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer

Takeda

Phase 1/2 Active not recruiting
334 enrolled 1 FDA
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04051827 2025-07-28

Drug-Drug Interaction Study of TAK-788 and Midazolam in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)

Takeda

Phase 1 Completed
26 enrolled 21 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04576208 2020-12-17

A Study to Evaluate the Impact of Management Strategies on Gastrointestinal-Related Adverse Events in Participants With Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations Receiving TAK-788

Takeda

Phase 2 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡